Apitope starts preclinical advancement of ATX-GD-459 for Graves’ disease treatment Initiates Preclinical Development of Peptide Therapy Apitope, the drug development and discovery company focused on disease-modifying treatments for sufferers with autoimmune and allergic illnesses, announced today that it all has started preclinical advancement of its novel peptide therapy ATX-GD-459 for the treating Graves' disease ed aide . Apitope, through its innovative discovery platform, has chosen three peptides in ATX-GD-459 which have the potential to treat and prevent the creation of stimulating antibodies against TSHR that lead to Graves' disease.
The FDA declined to touch upon pending litigation and the Justice Division said it could review the appeals courtroom ruling. Public health organizations are urging the government to appeal. Joining North Carolina-centered R.J. Reynolds, owned by Reynolds American Inc., and Lorillard Tobacco, owned by Lorillard Inc., in the lawsuit are Commonwealth Brands Inc., Liggett Group LLC and Santa Fe Natural Tobacco Company Inc. Richmond, Va.-structured Altria Group Inc., mother or father company of the nation’s largest cigarette maker, Philip Morris USA, making the top-selling Marlboro brand, is not a section of the lawsuit. The case is separate from a lawsuit by many of the same tobacco companies over this year’s 2009 Family Smoking Prevention and Tobacco Control Action, which cleared the true way for the more graphic warning labels and additional marketing restrictions.